AbbVie’s Humira loss of exclusivity has been a missed opportunity for competitors
Planning ahead, AbbVie positioned its next-generation therapies Skyrizi and Rinvoq as replacements to Humira.
18 July 2024
18 July 2024
Planning ahead, AbbVie positioned its next-generation therapies Skyrizi and Rinvoq as replacements to Humira.
The company also recorded a substantial rise in both operating income and net sales.
EPS saw a decline of 5.9% to $1.9, down from $2.05 per share in the previous year.
Approval of tabelecleucel would mark the first available therapy for the treatment of EBV+PTLD in the US.
The funds will finance late-stage trials of CRD-750, a PDE9 inhibitor for heart failure; and CRD-4730, a CaMKII inhibitor.
The approval is backed by data from the Phase III EMPOWUR trial in 1,515 patients.
The new funding is set to fund the expansion of the company’s Phase IIb studies into visugromab in combination with checkpoint inhibitors.
The company will also establish a US hub in Cambridge, Massachusetts in the second half of 2024.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.